282 related articles for article (PubMed ID: 20046149)
1. Management of individuals requiring antiretroviral therapy and TB treatment.
Cohen K; Meintjes G
Curr Opin HIV AIDS; 2010 Jan; 5(1):61-9. PubMed ID: 20046149
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries.
Maartens G; Decloedt E; Cohen K
Antivir Ther; 2009; 14(8):1039-43. PubMed ID: 20032533
[TBL] [Abstract][Full Text] [Related]
3. Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians.
van Oosterhout JJ; Kumwenda JJ; Beadsworth M; Mateyu G; Longwe T; Burger DM; Zijlstra EE
Antivir Ther; 2007; 12(4):515-21. PubMed ID: 17668560
[TBL] [Abstract][Full Text] [Related]
4. Tuberculosis and HIV co-infection: a practical therapeutic approach.
Breen RA; Swaden L; Ballinger J; Lipman MC
Drugs; 2006; 66(18):2299-308. PubMed ID: 17181373
[TBL] [Abstract][Full Text] [Related]
5. Tuberculosis and HIV co-infection: screening and treatment strategies.
Venkatesh KK; Swaminathan S; Andrews JR; Mayer KH
Drugs; 2011 Jun; 71(9):1133-52. PubMed ID: 21711060
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/μL: TB-HAART Study, a Randomized Clinical Trial.
Amogne W; Aderaye G; Habtewold A; Yimer G; Makonnen E; Worku A; Sonnerborg A; Aklillu E; Lindquist L
PLoS One; 2015; 10(5):e0122587. PubMed ID: 25966339
[TBL] [Abstract][Full Text] [Related]
7. Timing of antiretroviral therapy for HIV in the setting of TB treatment.
Piggott DA; Karakousis PC
Clin Dev Immunol; 2011; 2011():103917. PubMed ID: 21234380
[TBL] [Abstract][Full Text] [Related]
8. The tuberculosis-associated immune reconstitution inflammatory syndrome: recent advances in clinical and pathogenesis research.
Walker NF; Stek C; Wasserman S; Wilkinson RJ; Meintjes G
Curr Opin HIV AIDS; 2018 Nov; 13(6):512-521. PubMed ID: 30124473
[TBL] [Abstract][Full Text] [Related]
9. Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins.
Regazzi M; Carvalho AC; Villani P; Matteelli A
Clin Pharmacokinet; 2014 Jun; 53(6):489-507. PubMed ID: 24777631
[TBL] [Abstract][Full Text] [Related]
10. Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study.
Sinha S; Gupta K; Tripathy S; Dhooria S; Ranjan S; Pandey RM
BMC Infect Dis; 2017 Dec; 17(1):761. PubMed ID: 29228918
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
[TBL] [Abstract][Full Text] [Related]
12. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.
Manosuthi W; Mankatitham W; Lueangniyomkul A; Chimsuntorn S; Sungkanuparph S
HIV Med; 2008 May; 9(5):294-9. PubMed ID: 18400076
[TBL] [Abstract][Full Text] [Related]
13. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial.
Bonnet M; Bhatt N; Baudin E; Silva C; Michon C; Taburet AM; Ciaffi L; Sobry A; Bastos R; Nunes E; Rouzioux C; Jani I; Calmy A;
Lancet Infect Dis; 2013 Apr; 13(4):303-12. PubMed ID: 23433590
[TBL] [Abstract][Full Text] [Related]
14. Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?
Orrell C; Cohen K; Conradie F; Zeinecker J; Ive P; Sanne I; Wood R
Antivir Ther; 2011; 16(4):527-34. PubMed ID: 21685540
[TBL] [Abstract][Full Text] [Related]
15. Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome after early initiation of antiretroviral therapy in a randomized clinical trial.
Laureillard D; Marcy O; Madec Y; Chea S; Chan S; Borand L; Fernandez M; Prak N; Kim C; Dim B; Nerrienet E; Sok T; Delfraissy JF; Goldfeld AE; Blanc FX;
AIDS; 2013 Oct; 27(16):2577-86. PubMed ID: 24096631
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.
Boulle A; Van Cutsem G; Cohen K; Hilderbrand K; Mathee S; Abrahams M; Goemaere E; Coetzee D; Maartens G
JAMA; 2008 Aug; 300(5):530-9. PubMed ID: 18677025
[TBL] [Abstract][Full Text] [Related]
17. Antiretroviral drug-resistant mutations at baseline and at time of failure of antiretroviral therapy in HIV type 1-coinfected TB patients.
Rajesh L; Karunaianantham R; Narayanan PR; Swaminathan S
AIDS Res Hum Retroviruses; 2009 Nov; 25(11):1179-85. PubMed ID: 19895208
[TBL] [Abstract][Full Text] [Related]
18. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
[TBL] [Abstract][Full Text] [Related]
19. Dyslipidemia among HIV-infected Patients with tuberculosis taking once-daily nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in India.
Padmapriyadarsini C; Ramesh Kumar S; Terrin N; Narendran G; Menon PA; Ramachandran G; Subramanyan S; Venkatesan P; Wanke C; Swaminathan S
Clin Infect Dis; 2011 Feb; 52(4):540-6. PubMed ID: 21252141
[TBL] [Abstract][Full Text] [Related]
20. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis.
Jiang HY; Zhang MN; Chen HJ; Yang Y; Deng M; Ruan B
Int J Infect Dis; 2014 Aug; 25():130-5. PubMed ID: 24911886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]